Screener
Alnylam Pharmaceuticals ALNY Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Alnylam Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
FAQ
- What is Alnylam Pharmaceuticals's debt-to-equity?
- Alnylam Pharmaceuticals (ALNY) reported debt-to-equity of 0.2× in Q2 2026.
- How has Alnylam Pharmaceuticals's debt-to-equity changed year-over-year?
- Alnylam Pharmaceuticals's debt-to-equity decreased by 82.5% year-over-year, from 1.1× to 0.2×.
- What is the long-term trend for Alnylam Pharmaceuticals's debt-to-equity?
- Over 3 years (2020 to 2025), Alnylam Pharmaceuticals's debt-to-equity has grown at a -12.6% compound annual growth rate (CAGR), from 0.5× to 0.3×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Alnylam Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude